Cyr61 decreases Cytarabine chemosensitivity in acute lymphoblastic leukemia cells via NF-κB pathway activation

YINGPING CAO1*, CONGLIAN WU1,2*, YANFANG SONG3, ZHEN LIN1, YANLI KANG1, PINGXIA LU1, CHENQING ZHANG1, QINGHUA HUANG1, TAISEN HAO4, XIANJIN ZHU4 and JIANDA HU1,5*

1Department of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001; 2Department of Laboratory Medicine, The First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian 362000; 3Department of Laboratory Medicine, Clinical Laboratory, The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350001, P.R. China; 4Department of Cancer Biology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA; 5Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian Province Key Laboratory of Hematology, Fuzhou, Fujian 350001, P.R. China

Received August 9, 2018; Accepted November 11, 2018

DOI: 10.3892/ijmm.2018.4018

Abstract. Elevated Cyr61 levels have been reported in various malignancies. Elevation of Cyr61 protein levels contributes to the proliferation, metastasis, and chemotherapy resistance of malignant cells. Previously, it was discovered that Cyr61 is elevated in both the plasma and the bone marrow supernatants of patients with acute lymphoblastic leukemia (ALL), promoting ALL cell survival. However, the role of Cyr61 in the chemotherapeutic resistance of ALL cells remains unknown. The aim of the current study was to investigate the role of Cyr61 in regulating ALL cell chemosensitivity to Ara-C. It was found that Cyr61 is overexpressed in bone marrow mononuclear cells from patients with ALL. Increased Cyr61 effectively decreased Ara-C-induced apoptosis of ALL cells, and its function was blocked by the use of the anti-Cyr61 monoclonal antibody 093G9. Furthermore, Cyr61 increased the level of Bcl-2 in Ara-C-treated ALL cells. Mechanistically, it was shown that Cyr61 affected ALL cell resistance to Ara-C partially via the NF-κB pathway. Taken together, the present study is the first, to the best of our knowledge, to reveal that Cyr61 is involved in ALL cell resistance through the NF-κB pathway. The findings support a functional role for Cyr61 in promoting chemotherapy resistance, suggesting that targeting Cyr61 directly or its relevant effector pathways may improve the clinical responses of patients with ALL.

Introduction

Acute lymphoblastic leukemia (ALL) is an aggressive hematological malignancy that is mainly diagnosed in children. ALL arises from the malignant transformation of T or B progenitor cells in the bone marrow (BM) (1,2). Current multi-agent chemotherapy regimens are highly effective in patients with newly-diagnosed ALL (3); however, a significant number of patients relapsed due to chemotherapy failure. Resistance to chemotherapeutic agents is one of the major obstacles for the successful treatment of ALL (3,4).

Previous studies showed that the mechanism of resistance to chemotherapeutics agents is a complex network involving multiple cellular and molecular mechanisms. In ALL, the BM microenvironment provides growth and survival signals that may confer resistance to chemotherapy (5-7). Increasing evidence suggest that soluble factors in BM, including extracellular matrix molecules, cytokines, and chemokines such as osteopontin, CXCL12, and interleukin-6 (8,9), provide a permissive environment for leukemogenesis and contribute to drug resistance (10,11). Thus, studies on soluble factors in BM provide a better understanding of the drug resistance of ALL and facilitate the design of new treatments.

Cyr61/CCN1 is a secreted extracellular matrix (ECM) protein, which is important for cell proliferation, survival, adhesion, migration, and differentiation (12). As a secreted protein, the role of Cyr61 has been extensively investigated in solid tumors, with multiple studies showing that Cyr61 positively regulates tumor cell growth and metastasis (13-16). More and more studies have shown that Cyr61 confers on malignant cells resistance to chemotherapeutic drugs in breast cancer, ovarian cancer, prostate carcinoma and pancreatic ductal adenocarcinoma (17-20). Notably, Cyr61 is also involved in stroma-induced chemo-resistance in acute myeloid leukemia (AML) (21). In 2016, it was found that the levels of
Cyr61 are elevated in the plasma and BM supernatants from patients with ALL compared with in samples from healthy donors. It was also shown that increased Cyr61 promotes ALL cell survival (22). However, whether Cyr61 is involved in ALL cell resistance to chemotherapeutic drugs has not yet been explored.

In the present study, it was revealed that Cyr61 is highly expressed in BM mononuclear cells (BMMNCs) from patients with ALL compared with those from healthy donors. Furthermore, the role of Cyr61 in the chemotherapeutic sensitivity of ALL cells was determined. Given that Cytosine arabinoside (Ara-C) is one of the most important chemotherapeutic agents used to treat both children and adults with acute leukemia (3), our study used Ara-C to evaluate the role of Cyr61 in the chemotherapy resistance of ALL cells. The present study found that Cyr61 could protect ALL cells from Ara-C-induced apoptosis and that its effectiveness might be partially due to the activation of the NF-kB pathway. Furthermore, it was found that blocking the bioactivity of Cyr61 with an anti-Cyr61 antibody 093G9 could improve the ALL cell response to Ara-C. Therefore, the results indicated that Cyr61 may act as a chemoprotective factor for ALL cells, and that targeting Cyr61 directly, or its relevant effector pathways, might improve the clinical responses of patients with ALL.

Materials and methods

Reagents and chemicals. Recombinant human (rh) Cyr61 was obtained from PeproTech, Inc. (Rocky Hill, NJ, USA), dissolved in PBS to a stock concentration of 1 mg/ml and stored at 80˚C until used. Ara-C was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany), dissolved in DMSO to a stock concentration of 0.5 mM and stored at -20˚C until used. A mouse anti-human Cyr61 monoclonal antibody (093G9) and a PEGFP-Cyr61 plasmid were kindly gifted by Dr Ningli Li (Shanghai Jiao Tong University School of Medicine, Shanghai, China). Rabbit anti-human monoclonal antibodies (mAb) against GAPDH (1:1,000; cat. no. 8884S), Bcl-2 (1:1,000; cat. no. 4223S), NF-κB p65 (1:1,000; cat. no. 4764S) and p-NF-κB p-p65 (1:1,000; cat. no. 3033S) used were all purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). An HRP-linked anti-rabbit IgG and HRP-linked anti-mouse IgG were purchased from Cell Signaling Technology, Inc. Pyrrolidine dithiocarbamate (PDTC; special inhibitor of NF-κB activation) was purchased from Sigma-Aldrich (Merck KGaA).

Patients and specimens. All bone marrow (BM) aspirate samples were obtained from Fujian Medical University Union Hospital (Fuzhou, China) from July 2015 to October 2017. To analyze the level of Cyr61 in the BM mononuclear cells (BMMNCs) from patients with ALL, BM samples from newly diagnosed, non-treated patients with ALL (range, 6-37 years, n=8) and healthy donors (range, 16-34, n=6) were collected (Table I) and enriched for BMMNCs using histopaque gradient (density 1.077 g/ml; Sigma-Aldrich; Merck KGaA) according to the manufacturer’s instructions. The BM supernatant samples were obtained after centrifugation of the total BM aspirates of consecutive patients with ALL and stored at -80˚C until used. These studies were performed in accordance with the ethical guidelines under the protocols approved by the Institutional Medical Ethics Review Board of the Fujian Medical University Union Hospital. Informed consent was obtained from all individual participants included in the study.

Cell lines and culture conditions. Leukemia cell lines Jurkat and Nalm-6 cells were kindly provided by Dr Qiang Chen (Shanghai Jiao Tong University School of Medicine) and were maintained in RPMI-1640 medium (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 mg/ml streptomycin at 37˚C and 5% CO₂.

Evaluation of Cyr61’s effect on ALL cell chemosensitivity and antibody neutralization assays. To address the effect of BM-derived Cyr61 on the chemotherapeutic sensitivity to Ara-C of ALL cells, ALL cells were cultured using BM supernatants from patients with ALL in which overexpressed Cyr61 had been blocked with 1,000 pg/ml 093G9. A murine isotype-matched antibody served as the control. Cells were then treated with 1 µM Ara-C for 24 h and apoptotic cells were quantified by Annexin V-FITC and PI double-staining kit (BD Biosciences, San Jose, CA, USA).

Next, to explore rhCyr61’s effect on chemosensitivity in ALL, Jurkat (5x10⁵ cells/ml) and Nalm-6 (1x10⁶ cells/ml) cells were seeded into 24-well plates (CoStar, Cambridge, MA, USA) and maintained in RPMI-1640 medium with 5% FBS. Jurkat and Nalm-6 were pre-incubated with rhCyr61 at different concentrations for 24 h followed by treatment with 1 µM Ara-C. After incubation for 24 h, cell apoptosis was analyzed by Annexin V-FITC and PI double-staining kit (BD Biosciences). For the antibody blocking assay, rhCyr61 was pre-incubated with a mouse anti-Cyr61 mAb (093G9) for 2 h prior to adding to cell culture. A murine isotype-matched antibody served as a control. After incubation for 24 h, Jurkat and Nalm-6 cells were treated with 1 µM Ara-C for another 24 h. Cell apoptosis was analyzed using an Annexin V-FITC and PI Double-Staining kit (BD Biosciences).

Apoptosis assay. Cell apoptosis was measured according to the manufacturer’s instruction (BD Biosciences). The percentages of cell apoptosis (FITC-positive) were analyzed by flow cytometry using BD FACS Canto II flow cytometer and BD FACS Diva 6.0 software (BD Biosciences).

Transfection and Ara-C induced apoptosis assay. To construct Cyr61-overexpressing ALL cell models, Jurkat and Nalm-6 cells were transfected with PEGFP-Cyr61 (the plasmid carrying Cyr61 cDNA) using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in serum-free RPMI-1640 according to the manufacturer’s instructions. ALL cells were transfected with PEGFP-N3 (vector only) to generate matched control cells. After transfection, cells were washed and then incubated in RPMI-1640 medium with 10% FBS for 48 h. For the apoptosis assay, the transfected cells were treated with 1 µM Ara-C for 24 h. The cells were then washed in 1X PBS and stained with Annexin V-PE.
Table I. Clinical characteristics of patients with ALL included in the present study.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>ALL (n=8)</th>
<th>Control (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Female</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Age (years)</td>
<td>20.15±12.78</td>
<td>21.63±7.25</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T-ALL</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>B-ALL</td>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>

(BD Biosciences) according to the manufacturer's instructions. The percentages of apoptotic Jurkat or Nalm-6 cells (PE-positive) were subsequently analyzed by flow cytometry using a BD FACS Canto II flow cytometer and BD FACSDiva software 6.0 (BD Biosciences).

Real-time PCR. Jurkat and Nalm-6 were treated with Ara-C (1 μM) with or without rhCyr61 (100 ng/ml for Jurkat and 1,000 ng/ml for Nalm-6) for 8 h before RNA extraction. Total RNA was extracted from specimens using a TriPure Isolation Reagent (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. Total RNA (1 μg) was reverse transcribed into first strand cDNA using the RevertAid™ First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Total RNA showed that Cyr61 protein was expressed in both Jurkat and Nalm-6 cells, and that the level of Cyr61 protein in Jurkat cells was approximately 1.5-fold higher than in Nalm-6 cells. The expression of Cyr61 in Jurkat and Nalm-6 was examined in the BMMNCs derived from eight patients with ALL and six healthy donors via western blotting, and statistical analysis was performed with SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA). The difference in Cyr61 expression between patients with ALL and healthy donors was analyzed by the non-parametric Mann-Whitney U test. Statistical comparisons of means between two groups were analyzed using the Student's t-test. Comparisons among multiple groups were analyzed using one-way ANOVA with a post hoc SNK test for comparisons. P<0.05 was considered to indicate a statistically significant difference.

Results

Level of Cyr61 expression in ALL cell lines and ALL bone marrow samples. It was previously observed that Cyr61 is expressed in both the plasma and BM supernatants from patients with ALL. In this study, the levels of Cyr61 protein were examined in the BMMNCs derived from eight patients with ALL and six healthy donors via western blotting, and the results showed that Cyr61 levels in the BMMNCs derived from patients increased to varying levels compared with those derived from healthy donors (Fig. 1A). Further analysis showed that Cyr61 protein was expressed in both Jurkat and Nalm-6 cells, and that the level of Cyr61 protein in Jurkat cells was approximately 1.5-fold higher than in Nalm-6 cells (P<0.01, Student’s t-test; Fig. 1B). Taken together, these data indicate that the level of Cyr61 is upregulated in ALL bone marrow samples, and that ALL cell lines (Jurkat and Nalm-6) also express the Cyr61 protein.

Cyr61 effectively decreases Ara-C-induced apoptosis in ALL cells. Previous studies have shown that Cyr61 is involved in drug resistance by decreasing chemotherapeutic drug-induced apoptosis in ovarian cancer, breast cancer and acute myeloid leukemia cells (21,25,26). To explore the role of Cyr61 in the drug resistance of ALL, Jurkat (T-ALL cell lines) and Nalm-6 (B-ALL cell lines) cells were incubated with BM supernatants...
from newly diagnosed patients with ALL with no treatment. Cell cultures were subjected to Ara-C treatment in the presence or absence of an anti-Cyr61 monoclonal antibody (mAb) 093G9. As shown in Fig. 2A, anti-Cyr61 monoclonal antibody (mAb) 093G9 could increase the Ara-C-induced Jurkat and Nalm-6 cell apoptosis, suggesting that the endogenous Cyr61 from ALL patient BM could decrease ALL cell apoptosis induced by Ara-C. Next, Jurkat and Nalm-6 cells were transiently transfected with a Cyr61-expressing plasmid (PEGFP-Cyr61) to overexpress Cyr61 in ALL cells. Transfection with PEGFP-Cyr61 significantly increased the level of Cyr61 protein in both Jurkat and Nalm-6 cells (data not shown). As expected, Ara-C-induced apoptosis was significantly decreased in Cyr61-overexpressing (PEGFP-Cyr61) ALL cells (Fig. 2B), suggesting that autocrine secretion of Cyr61 could confer resistance to Ara-C-induced apoptosis. To further address Cyr61's effect on the chemosensitivity of ALL cells, Jurkat and Nalm-6 cells were treated with exogenous Cyr61 (rhCyr61) at different concentrations, and cellular sensitivity to Ara-C-induced apoptosis was subsequently examined. As shown in Fig. 2C, exogenous Cyr61 also significantly downregulated the level of Ara-C-induced apoptosis in Jurkat and Nalm-6 cells in a dose-dependent manner. Then, Jurkat and Nalm-6 cells were treated with an anti-Cyr61 monoclonal antibody 093G9 to block rhCyr61 function, and the apoptosis induced by Ara-C were analyzed. The results showed that exposure to 093G9 significantly sensitized both Jurkat and Nalm-6 cells to Ara-C treatment, resulting in increased apoptosis (Fig. 2D). Taken together, these results suggest that Cyr61 has an important role in the resistance of ALL cells to Ara-C.

Exogenous Cyr61 decreases Ara-C-induced apoptosis through the NF-κB signaling pathway. Several reports have observed constitutive NF-κB activation in ALL cells (29-31); this pathway could be activated by Cyr61, resulting in cellular proliferation and chemotherapy resistance in ovarian and breast cancer cells. To determine whether the NF-κB pathway is involved in the anti-apoptotic function of Cyr61 in Ara-C-treated ALL cells, we evaluated the profile of the NF-κB pathway using known inhibitors of this pathway, including PDTC (an inhibitor of NF-κB activation). The results showed that PDTC could significantly increase Ara-C-induced apoptosis in Cyr61-treated ALL cells and PDTC alone have no effect on the apoptosis of ALL cells (Fig. 4A). Moreover, Cyr61 treatment led to a drastic increase in the phosphorylation of NF-κB but not its overall expression in both Jurkat and Nalm-6 cells (Fig. 4B), indicating Cyr61 could activate NF-κB pathway in Jurkat and Nalm-6

**Figure 1. Level of Cyr61 expression in ALL cell lines and ALL bone marrow samples.** (A) Cyr61 protein levels were determined in the BMMNCs derived from healthy donors and ALL samples by western blotting, and the ratio of Cyr61/GAPDH in the last ALL BM sample was taken as the control, and the ratio of Cyr61/GAPDH was set as 1, to calculate the relative expression of Cyr61 in other samples. (B) The level of Cyr61 protein was determined in two ALL cell lines (Jurkat and Nalm-6) by western blotting, and the ratio of Cyr61/GAPDH in Nalm-6 cells was taken as the control, in which the ratio of Cyr61/GAPDH was set as 1, to calculate the relative expression of Cyr61 in Jurkat cells. *P<0.05. Cyr61, cysteine-rich 61; ALL, acute lymphoblastic leukemia; BMMNCs, bone marrow mononuclear cells; BM, bone marrow; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Figure 2. Cyr61 effectively decreases Ara-C-induced apoptosis in ALL cells. (A) Jurkat and Nalm-6 cells were incubated in BM supernatants (Cyr61 concentration is 185 pg/ml) from patients with ALL with or without 1,000 pg/ml anti-human Cyr61 monoclonal antibody (093G9) for 24 h, followed by exposure to 1 µM Ara-C. After incubation for 24 h, cells were collected and stained with Annexin V-FITC/PI and the percentages of apoptotic cells (FITC-positive) were measured using flow cytometric analysis. A murine isotype-matched antibody (con-IgG) served as a control. (B) Jurkat and Nalm-6 cells were transfected with a Cyr61 expression plasmid (PEGFP-Cyr61) and an empty plasmid (PEGFP-N3) for 48 h followed by exposure to 1 µM Ara-C for 24 h. Cells were then collected and stained with Annexin V-PE. The percentages of apoptotic cells (PE-positive) were measured with flow cytometric analysis. (C) Jurkat and Nalm-6 cells were pre-incubated with increasing concentrations of rhCyr61 for 24 h, followed by exposure to 1 µM Ara-C for 24 h. Cell apoptosis was determined by flow cytometric analysis using Annexin V-FITC/PI double staining. (D) Cyr61-decreased apoptosis of Ara-C-induced ALL cells was restored by 093G9. rhCyr61 (100 ng/ml Cyr61 in Jurkat; 1,000 ng/ml Cyr61 in Nalm-6) were pre-incubated with a mouse anti-Cyr61 mAb (093G9) (500 ng/ml in Jurkat; 5,000 ng/ml in Nalm-6) for 2 h prior to adding to cell culture. A murine isotype-matched antibody (con-IgG) served as a control. After incubation for 24 h, Jurkat and Nalm-6 cells were treated with 1 µM Ara-C for another 24 h. Cell apoptosis was analyzed using an Annexin V-FITC/PI double-staining kit. Data are expressed as the mean percentage of apoptotic cells ± SEM of at least three independent experiments in triplicate. *P<0.05, **P<0.01. Cyr61, cysteine-rich 61; ALL, acute lymphoblastic leukemia; Ara-C, cytosine arabinoside; PI, propidium iodide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
CAO et al. | Cyr61 DECREASES CYTARABINE-INDUCED ALL CELL APOPTOSIS

...cells. Taken together, these results suggest that Cyr61 decreases Ara-C-induced apoptosis via the NF-κB pathway.

*Ara-C treatment increases the production of Cyr61 in ALL cells.* To explore whether Ara-C can affect the production of Cyr61 in ALL cells, Jurkat and Nalm-6 cells were exposed to Ara-C for 24 h. Western blotting was used to analyze the expression profiles of Cyr61 in ALL cells. As shown in Fig. 5, Ara-C could increase the production of Cyr61 in ALL cells.

**Discussion**

In this study, we found that Cyr61 was overexpressed in ALL BMMNCs. Furthermore, we observed that Cyr61 effectively decreased Ara-C-induced apoptosis in ALL cells, indicating chemoprotective effects of Cyr61 in ALL treatment.

Cyr61 is a secreted ECM protein, which is not only important for cell proliferation, survival, and migration, but also drug resistance in various tumors (12). It was recently reported that the level of Cyr61 is increased in BM supernatants from patients with ALL, and this change could promote ALL cell survival (22). Previous studies showed that BM stromal cells are the major source of Cyr61 (21,32). Our current study showed that Cyr61 was overexpressed not only in the BMMNCs from patients with ALL, but also two ALL cell lines. It is speculated that, in addition to stromal cells, ALL cells could also be one of the sources generating Cyr61 in the bone marrow in an autocrine manner.
Although multi-agent chemotherapy regimens are highly effective for patients with ALL, some responding patients eventually became refractory to initial therapy (3). Resistance to chemotherapeutic agents is a significant clinical problem for the successful treatment of leukemia. More studies have shown that the BM microenvironment contributes to leukemia cell resistance to chemotherapeutic agents. However, no study has yet explored the role of Cyr61 in ALL drug resistance, to the best of our knowledge.

Induction of apoptosis is a critical mechanism of cytotoxicity mediated by chemotherapeutic drugs, and resistance to apoptosis is a major obstacle in chemotherapy treatment (33,34).

In the present study, it was found that BM-derived Cyr61 could decrease Ara-C-induced apoptosis in Jurkat and Nalm-6 cells, and forced overexpression of Cyr61 in ALL cells enhanced their resistance to Ara-C-induced apoptosis, possibly through the autocrine secretion of Cyr61 into the microenvironment. In addition, it was observed that recombinant human Cyr61 increased the resistance of ALL cells to Ara-C, and that this effect was antagonized by the anti-Cyr61 antibody 093G9. Furthermore, it was observed that Jurkat cells (T-ALL cell lines) were more sensitive to the chemoprotective effects of Cyr61 than Nalm-6 cells (B-ALL cell lines), indicating that Cyr61 has differential chemoprotective effects on diverse cell types. These
findings demonstrate, for the first time, that Cyr61 decreases the sensitivity of ALL cells to Ara-C, and that inhibition of the bioactivity of Cyr61 restores ALL cell response to Ara-C. The findings reported herein are consistent with previous results that Cyr61 decreases the apoptosis of tumor cells, leading to chemotherapy resistance in breast cancer, ovarian cancer and acute myeloid leukemia (21,25,26). Therefore, Cyr61 may be one of the factors leading to drug resistance of ALL, and blocking pathways involved with Cyr61 function could be used for treating relapsed ALL. These results provide further evidence that BM microenvironment-derived soluble factors have important roles in the development and therapeutic response of leukemia cells.

It is well known that the Bcl-2 family of proteins are important apoptosis regulators that have essential roles in the apoptosis induced by chemotherapeutic drugs (27,28). To investigate the mechanism underlying Cyr61-induced drug resistance, the influence of exogenous Cyr61 on the expression of Bcl-2, BCL-xL, Bax, and XIAP was evaluated as a possible mechanism for Cyr61-induced Ara-C resistance. The results showed that Cyr61 could increase Bcl-2 production without affecting the expression levels of BCL-xL, Bax, and XIAP in Ara-C-treated ALL cells. Considering that Bcl-2 is an anti-apoptotic protein able to inhibit apoptosis, these findings suggest that the Bcl-2 pathway is involved in Cyr61-induced Ara-C resistance of ALL cells. Furthermore, it was found that Cyr61-induced Bcl-2 production is higher in Jurkat cells than in Nalm-6 cells, which may be one of the reasons why Jurkat cells were more sensitive to Cyr61 chemoprotective effects than Nalm-6 cells.

Previous studies have shown that NF-κB is activated downstream of Cyr61, conferring malignant cell resistance to chemotherapy (17,18). As expected, the NF-κB pathway also contributed to Cyr61-mediated ALL cell resistance to Ara-C. The findings reported herein are consistent with those of several previous reports in which Cyr61 activates the NF-κB signaling pathway, and subsequently confers resistance to certain chemotherapeutic drugs in breast cancer and ovarian cancer (17,18). Numerous studies have demonstrated that the Bcl-2 family and NF-κB proteins are closely associated with cell apoptosis (35-37). Notably, our previous studies found that the NF-κB signaling pathway is involved in Cyr61-induced Bcl-2 production in ALL cells (22). On the basis of these results, NF-κB proteins may be upstream controllers of Bcl-2 production in Cyr61-induced ALL cell resistance to Ara-C.

The ability of cells to counteract stressful conditions usually elicits the activation of pro-survival pathways and the production of molecules with antioxidant and anti-apoptotic activities to sustain cell survival. For example, Cyr61 is found to be markedly increased in prostate carcinoma PC-3 cells in response to N-acetylcysteine induced cytotoxicity, and are beneficial for cell survival and anti-apoptosis under cytotoxic microenvironment (19). In the present study, the results showed that Ara-C treatment markedly increased the levels of Cyr61 in Jurkat and Nalm-6 cells. Therefore, it is speculated that this is a part of the mechanism of ALL cell resistance to Ara-C. Thus, the significance and mechanism of Ara-C-induced Cyr61 expression need to be further studied.

There are several limitations to this study. First, the results rely solely on one chemotherapy drug (Ara-C). However, there are many alternative chemotherapeutic drugs commonly used for ALL treatment, such as vincristine, daunorubicin, and dexamethasone. The role of Cyr61 in the chemosensitivity of ALL cells to other drugs remains unknown and needs to be elucidated. Second, the study on the Cyr61/NF-κB signaling pathway was performed in vitro and thus lacks certain components of the BM microenvironment; further study should be conducted to elucidate the mechanism underlying Cyr61-mediated ALL cell resistance to Ara-C in vivo.

In the present study, the results showed that Cyr61 was highly expressed in BMMNCs from patients with ALL, and elevated Cyr61 levels conferred ALL cells with resistance to Ara-C-induced apoptosis, partially via the activation of the NF-κB pathway. The present study indicates, for the first time, that Cyr61 may act as a chemoprotective factor for ALL cells, and that targeting Cyr61 directly or its relevant effector pathways might improve the clinical responses of patients undergoing treatment for ALL.

**Funding**

This study was supported by the Fujian Medical Innovation Project (grant no. 2017- CX-20), Fujian Province Joint Funds for the Innovation of Science and Technology (grant no. 2017Y9051), the Natural Science Foundation of Fujian Province (grant no. 2016J01569), the Training Project for Young and Middle-aged Core Talents in Health System of Fujian Province (grant nos. 2016-ZQN-31 and 2018-ZQN-69), the National Natural Science Foundation of China (grant no. 81700098), the Fujian Provincial Key Special Projects (grant nos. 2016Y9032 and 2016B041), the Construction Project of Fujian Medical Center of Hematology (grant no. Min201704), the National Key R&D Program of China (grant no. 2016YFC0902800), the National Natural Science Foundation of China (grant no. 81470326), Fujian Provincial Public Health Project (grant no. WKJ2016-2-06), National and Fujian Provincial Key Clinical Specialty Discipline Construction Program, P. R. C.
(grant no. 2016-682) and the Fujian Provincial National Health and Family Planning Commission Project for Young (grant no. 2016-1-45).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
XZ and JH conceived the research and performed overall supervision in the study. YC, CW, XZ, ZL, YK, PL, CZ, QH and TH performed the experiments. XZ, CW, YS, YC and JH performed data analysis. XZ, JH, YC and CW wrote the manuscript. XZ, JH, YC and CW contributed to the discussion of results and to the review of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
These studies were performed in accordance with the ethical guidelines under the protocols approved by the Institutional Medical Ethics Review Board of the Affiliated Union Hospital of Fujian Medical University, Fuzhou, China.

Patient consent for publication
Not applicable.

Competing financial interests
The authors declare no competing financial interests.

References